Citations
Measurable residual disease in hematological pathologies. Expert consensus. Asociación Colombiana de Hematología y Oncología (ACHO) - 2024
Enfermedad residual medible en patologías hematológicas. Consenso de expertos, Asociación Colombiana de Hematología y Oncología - 2024
Open | Download
How to Cite
1.
Orduz R, Rendón J, Romero M, Quijano-Gómez S, Caicedo-Ortiz I, Moreno L, et al. Measurable residual disease in hematological pathologies. Expert consensus. Asociación Colombiana de Hematología y Oncología (ACHO) - 2024. Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2025 Dec. 6];11(2):113-29. https://doi.org/10.51643/22562915.521
Download Citation
Section
Revisiones
How to Cite
1.
Orduz R, Rendón J, Romero M, Quijano-Gómez S, Caicedo-Ortiz I, Moreno L, et al. Measurable residual disease in hematological pathologies. Expert consensus. Asociación Colombiana de Hematología y Oncología (ACHO) - 2024. Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2025 Dec. 6];11(2):113-29. https://doi.org/10.51643/22562915.521
Dimensions
license
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Show authors biography
The hematolymphoid neoplasms are considered to be of high cost and have an impact on quality of life, for this reason the use of diagnostic and tests for follow-up such as Measurable Residual Disease (MRD) continues to be a tool to determine prognoses, considering new technologies and the importance of standardizing processing. Objective: To structure a series of considerations by common agreement of experts about Measurable Residual Disease in 5 hematological pathologies, in the Colombian context. Methods: A formal consensus of experts, mixed (Delphi/Nominal), was made from 23 context questions related to Measurable Residual Disease in 5 hematological pathologies. 2 qualifying rounds and a virtual nominal meeting were held. The information was analyzed in STATA 13. Results: 23 questions related to the diagnosis of Measurable Residual Disease in 5 hematological pathologies were constructed in the context of its use in Colombia. 17 health professionals (pathology and bacteriology) experts in Measurable Residual Disease by flow cytometry from Bogotá, Medellín, Cali, Bucaramanga, Cartagena, Rionegro, Barranquilla and Cúcuta participated and it was leading by the Colombian Association of Hematology and Oncology (ACHO). Conclusions: 23 considerations were defined to guide the use of flow cytometry for Measurable Residual Disease in 5 hematological pathologies, as well as to make a diagnosis of the context of this test in Colombia. Finally, this consensus aims to standardize this technique as well standardize clinical conducts between hemato-oncologists hoping to improve the decisions that are taken because this measurement in order to improve health´s patients.
Article visits 1422 | PDF visits 948
Downloads
Download data is not yet available.
- Uribe CJ, Meza EE, NJ. G. Incidencia de neoplasias hematológicas en el área metropolitana de Bucaramanga, 2000-2004. MedUNAB. [Internet] 2008;11(7):76-82. Disponible en: https://revistas.unab.edu.co/index.php/medunab/article/view/64/58
- Leukemia & Lynphoma Society. Minimal/Measurable Residual Disease (MRD). [Internet] 2019. Disponible en: https://www.lls.org/sites/default/files/2022-06/FS35_Minimal_Residual_Disease_2022 Final.pdf. Acceso: 2023.
- World Health Organization (WHO), International agency for research of cancer. Cancer Today France-Lyon. [Internet] 2022. Disponible en: https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&cancers=34&populations=900&multiple_populations=1&key=crude_rate&group_populations=1.
- Ministerio de Salud y Protección Social. Cuenta de Alto Costo - Cáncer (Leucemias y linfomas) Colombia. [Internet]. 2022. Disponible en: https://cuentadealtocosto.org/cancer/
- Martínez-Sánchez L, Jaramillo-Jaramillo L, Álvarez-Hernández L, Hernández-Restrepo F, Ruíz-Mejía C, et al. Enfermedad Mínima Residual en leucemia: rompiendo el paradigma de remisión completa. Revista Cubana de Hematología, Inmunología y Hemoterapia [Internet]. 2018;34(1):1-16. Disponible en: https://revhematologia.sld.cu/index.php/hih/article/view/881/766
- Cardona-Quiceno RA, Mejía-Pineda GS, López L, Ruíz-Mejía C, Jaramillo LI, et al. Detección por citometría de flujo de la enfermedad mínima residual en las leucemias agudas. Revista Cubana de Hematología, Inmunología y Hemoterapia [Internet]. 2021;37(3):e1428. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892021000300009
- Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom [Internet]. 2005;68(1):18-24. Disponible en: https://doi.org/10.1002/cyto.b.20071. DOI: https://doi.org/10.1002/cyto.b.20071
- Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood [Internet]. 2017;129(3):347-57. Disponible en: https://doi.org/10.1182/blood-2016-07-726307 DOI: https://doi.org/10.1182/blood-2016-07-726307
- Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia [Internet]. 2007;21(4):622-6. Disponible en: https://doi.org/10.1038/sj.leu.2404603. DOI: https://doi.org/10.1038/sj.leu.2404603
- Cárdenas-Araujo D, Gutiérrez-Aguirre CH. Métodos para detectar enfermedad mínima residual en leucemia linfoblástica aguda y su aplicación clínica. Rev Hematol Mex [Internet]. 2018;19(1):41-9. Disponible en: https://www.medigraphic.com/pdfs/hematologia/re-2018/re181e.pdf
- Blanquer MB, Algueró C, López RP, Cabañas-Perianes V. Protocolo de utilización e interpretación de pruebas moleculares en enfermedades hematológicas malignas. Medicine [Internet]. 2020;13(20):1159-62. Disponible en: https://doi.org/10.1016/j.med.2020.11.007 DOI: https://doi.org/10.1016/j.med.2020.11.007
- Martínez-Ezquerro JD, Ruiz-Cejudo SM, Bustamante-Fuentes A, Díaz-Badillo Á, García-Oropesa EM, López-Sosa EB, et al. Consenso experto en tiempos de COVID-19: aplicaciones del método Delphi en materia de salud. Cir Cir [Internet]. 2020;89(1):120-129. Disponible en: https://doi.org/10.24875/CIRU.20000936 DOI: https://doi.org/10.24875/CIRU.20000936
- Sánchez-Pedraza R, Jaramillo-González LE. Metodología de calificación y resumen de las opiniones dentro de consensos formales. Revista Colombiana de Psiquiatría [Internet]. 2009;38(4):777-785. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0034-74502009000400015
- Asociación Colombiana de Hematología y Oncología-ACHO, Fundación Universitaria de Ciencias de la Salud-FUCS. Guía de Práctica Clínica para el tratamiento de la leucemia linfocítica crónica. [Internet] 2022. Disponible en: https://repositorio.fucsalud.edu.co/bitstream/handle/001/1953/GPC-%20leucemia%20linfoc%C3%ADtica%20cr%C3%B3nica%20%28PROFESIONALES%29.pdf?sequence=1&isAllowed=y. Acceso: 2023.
- Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood [Internet]. 2006;107(3):1116-23. Disponible en: https://doi.org/10.1182/blood-2005-07-2708. DOI: https://doi.org/10.1182/blood-2005-07-2708
- Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am [Internet]. 2009;23(5):1083-98. Disponible en: https://doi.org/10.1016/j.hoc.2009.07.010. DOI: https://doi.org/10.1016/j.hoc.2009.07.010
- 17. Campana D. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol [Internet]. 2004;122(1-2):8-15. Disponible en: https://doi.org/10.1159/000077554. DOI: https://doi.org/10.1159/000077554
- Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. [Internet] 2017;31(10):2094-103. Disponible en: https://doi.org/10.1038/leu.2017.29. DOI: https://doi.org/10.1038/leu.2017.29
- Soh KT, Tario JD, Jr., Hahn TE, Hillengass J, McCarthy PL, et al. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. Cytometry B Clin Cytom [Internet]. 2020;98(2):161-73. Disponible en: https://doi.org/10.1002/cyto.b.21862 DOI: https://doi.org/10.1002/cyto.b.21862
- Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom [Internet]. 2016;90(1):61-72. Disponible en: https://doi.org/10.1002/cyto.b.21265. DOI: https://doi.org/10.1002/cyto.b.21265
- Coltoff A, Houldsworth J, Keyzner A, Renteria AS, Mascarenhas J. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion. Ann Hematol [Internet]. 2018;97(7):1155-67. Disponible en: https://doi.org/10.1007/s00277-018-3330-9. DOI: https://doi.org/10.1007/s00277-018-3330-9
- Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, Böttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia [Internet]. 2012;26(9):1986-2010. Disponible en: https://doi.org/10.1038/leu.2012.122. DOI: https://doi.org/10.1038/leu.2012.122
- Liu Z, Li Y, Shi C. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy. Int J Hematol [Internet]. 2021;113(3):337-43. Disponible en: https://doi.org/10.1007/s12185-021-03085-y. DOI: https://doi.org/10.1007/s12185-021-03085-y
- Yee AJ, Raje N. Minimal residual disease in multiple myeloma: why, when, where. Hematology. Am Soc Hematol Educ Program [Internet]. 2021;2021(1):37-45. Disponible en: https://doi.org/10.1182/hematology.2021000230. DOI: https://doi.org/10.1182/hematology.2021000230
- Narayanan D, Weinberg OK. How I investigate acute myeloid leukemia. International Journal of Laboratory Hematology [Internet]. 2020;42(1):3-15. Disponible en: https://doi.org/10.1111/ijlh.13135. DOI: https://doi.org/10.1111/ijlh.13135
- Dillon R, Potter N, Freeman S, Russell N. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). Br J Haematol [Internet]. 2021;193(2):231-44. Disponible en: https://doi.org/10.1056/NEJMoa1716863. DOI: https://doi.org/10.1111/bjh.17185
- Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, al Hinai A, Zeilemaker A, et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine [Internet]. 2018;378(13):1189-99. Disponible en: https://doi.org/10.1056/NEJMoa1716863. DOI: https://doi.org/10.1056/NEJMoa1716863
- Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica [Internet]. 2019;104(8):1532-41. Disponible en: https://doi.org/10.3324/haematol.2018.208454 DOI: https://doi.org/10.3324/haematol.2018.208454
- Cohen AD. Myeloma: next generation immunotherapy. Hematology Am Soc Hematol Educ Program [Internet]. 2019;2019(1):266-72. Disponible en: https://doi.org/10.1182/hematology.2019000068. DOI: https://doi.org/10.1182/hematology.2019000068
- Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood [Internet]. 2015;125(20):3059-68. Disponible en: https://doi.org/10.1182/blood-2014-11-568907. DOI: https://doi.org/10.1182/blood-2014-11-568907
- Bruce C, Mato A. Assessment of minimal residual disease (MRD) in chronic lymphocytic leukemia: a review of the data and future directions. Clin Adv Hematol Oncol [Internet]. 2020;18 Suppl 10(6):7-14. Disponible en: https://www.hematologyandoncology.net/files/2020/06/ho0620sup10-1.pdf
- Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. [Internet] 2021 Dec 30;138(26):2753-2767. Disponible en: https://doi.org/10.1182/blood.2021013626 DOI: https://doi.org/10.1182/blood.2021013626
Tutorials
About the journal
Information
Directories and Indexers
Plagiarism Check
Descriptor
Google Scholar profile
QR code
Keywords
Most read in the last 30 days
